{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:31:53Z","timestamp":1772130713377,"version":"3.50.1"},"reference-count":104,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T00:00:00Z","timestamp":1396915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the introduction of targeted agents primarily applicable to non\u2010small cell lung cancer (<jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content>) of adenocarcinoma histology, there is a heightened unmet need in the squamous cell carcinoma population. Targeting the angiogenic fibroblast growth factor (<jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>)\/<jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content> receptor (<jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content>) signaling pathway is among the strategies being explored in squamous <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content>; these efforts are supported by growth\u2010promoting effects of <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content> signaling in preclinical studies (including interactions with other pathways) and observations suggesting that <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content>\u2010related aberrations may be more common in squamous versus adenocarcinoma and other histologies. A number of different anti\u2010<jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content> approaches have shown promise in preclinical studies. Clinical trials of two multitargeted tyrosine kinase inhibitors are restricting enrollment to patients with squamous <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content>: a phase I\/<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trial of nintedanib added to first\u2010line gemcitabine\/cisplatin and a phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trial of ponatinib for previously treated advanced disease, with the latter requiring not only squamous disease but also a confirmed <jats:italic><jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content><\/jats:italic> kinase amplification or mutation. There are several ongoing clinical trials of multitargeted agents in general <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content> populations, including but not limited to patients with squamous disease. Other <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content>\u2010targeted agents are in earlier clinical development. While results are awaited from these clinical investigations in squamous <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content> and other disease settings, additional research is needed to elucidate the role of <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content> signaling in the biology of <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content> of different histologies.<\/jats:p>","DOI":"10.1002\/cam4.238","type":"journal-article","created":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T05:16:54Z","timestamp":1396934214000},"page":"681-692","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Fibroblast growth factor signaling and inhibition in non\u2010small cell lung cancer and their role in squamous cell tumors"],"prefix":"10.1002","volume":"3","author":[{"given":"Ravi","family":"Salgia","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology Department of Medicine University of Chicago Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,8]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"National Comprehensive Cancer Network.2013.NCCN Clinical Practice Guidelines in Oncology\u2122. Non\u2010Small Cell Lung Cancer. V.2.2013. Available athttp:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/nscl.pdf(accessed January 17 2013)."},{"key":"e_1_2_8_3_1","article-title":"Lung: non\u2010small cell lung carcinoma","author":"Heighway J.","year":"2012","journal-title":"Atlas Genet. Cytogenet. Oncol. Haematol"},{"key":"e_1_2_8_4_1","unstructured":"Iressa.2005.Iressa\u00ae(gefitinib tablets) [package insert].AstraZeneca Pharmaceuticals LP Wilmington DE."},{"key":"e_1_2_8_5_1","unstructured":"Tarceva.2013.Tarceva\u00ae(erlotinib tablets) [package insert].Genentech Inc. South San Francisco CA."},{"key":"e_1_2_8_6_1","unstructured":"XALKORI.2011.XALKORI\u00ae(crizotinib) Capsules oral [package insert].Pfizer Labs New York."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-010-0160-8"},{"key":"e_1_2_8_8_1","unstructured":"Avastin.2012.AVASTIN\u00ae(bevacizumab) Solution for intravenous infusion [package insert].Genentech Inc. South San Francisco CA."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.022"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1321"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9303"},{"key":"e_1_2_8_13_1","unstructured":"Amgen.2010.Independent Data Monitoring Committee Recommends Resuming Enrollment of Non\u2010squamous NSCLC Patients in the Motesanib MONET1 Trial. Available athttp:\/\/www.amgen.com\/media\/media_pr_detail.jsp?year=2009&releaseID=1255738(accessed May 12 2010)."},{"key":"e_1_2_8_14_1","first-page":"1459","article-title":"Biological characterization of subgroups of squamous cell lung carcinomas","volume":"5","author":"Mattern J.","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_8_15_1","first-page":"5117","article-title":"Comparison of serum growth factors and tumor markers as prognostic factors for survival in non\u2010small cell lung cancer","volume":"23","author":"Nieder C.","year":"2003","journal-title":"Anticancer Res."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020351"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001451"},{"key":"e_1_2_8_18_1","first-page":"725","article-title":"Increased FGFR1 copy number in lung squamous cell carcinomas","volume":"5","author":"Sasaki H.","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20101603"},{"issue":"3005","key":"e_1_2_8_20_1","article-title":"Fibroblast growth factors","volume":"2","author":"Ornitz D. M.","year":"2001","journal-title":"Genome Biol."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07423"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000426"},{"key":"e_1_2_8_23_1","first-page":"1125","article-title":"Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer","volume":"20","author":"Sasaki H.","year":"2008","journal-title":"Oncol. Rep."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-200055949"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(00)00187-2"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.11.005"},{"key":"e_1_2_8_27_1","first-page":"398","article-title":"Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer","volume":"22","author":"Slodkowska J.","year":"2000","journal-title":"Anal. Quant. Cytol. Histol."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.01.002"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21581"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014117"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-09-0460"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.049544"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2009.05.001"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00623-3"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0167"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-012-1250-y"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029671"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3388"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(02)00027-2"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.07.007"},{"key":"e_1_2_8_41_1","first-page":"5210","article-title":"Soluble syndecan\u20101 and serum basic fibroblast growth factor are new prognostic factors in lung cancer","volume":"62","author":"Joensuu H.","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2137"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2003.11.031"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.09.005"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8622"},{"key":"e_1_2_8_46_1","first-page":"1123","article-title":"Basic fibroblast growth factor and vascular endothelial growth factor in sera from non\u2010small cell lung cancer patients","volume":"18","author":"Brattstrom D.","year":"1998","journal-title":"Anticancer Res."},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31819f2e38"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181991d18"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(99)90139-9"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.50"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.08.048"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ae2844"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1154"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0444"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4409"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6307"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0193"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0450"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000329978"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0010"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1608-x"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2694"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.07.016"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr596"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318238154d"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.18_suppl.lba8011"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.9427"},{"key":"e_1_2_8_68_1","unstructured":"ERBITUX.2012.ERBITUX\u00ae(cetuximab) injection for intravenous infusion [package insert].ImClone LLC Branchburg NJ."},{"key":"e_1_2_8_69_1","doi-asserted-by":"crossref","first-page":"ixe22","DOI":"10.1016\/S0923-7534(20)34340-4","article-title":"ELUNG: A multicenter, randomized phase IIB trial of \u201cstandard\u201d platinum doublets plus cetuximab (CET) as first\u2010line treatment of recurrent or advanced non\u2010small cell lung cancer (NSCLC)","volume":"23","author":"Schwartzberg L. S.","year":"2012","journal-title":"Ann. Oncol."},{"key":"e_1_2_8_70_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.tps2626","article-title":"FGFR: Proof\u2010of\u2010concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours","volume":"31","author":"Smyth E. C.","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.05.012"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2207"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1130"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1771"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1045"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.073"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208705"},{"key":"e_1_2_8_78_1","first-page":"8108","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder","volume":"63","author":"Bakkar A. A.","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64665-2"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh275"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25651"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013821"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200883"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.46"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1159\/000317055"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0803379105"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210529"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0770"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182a46fe9"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0323"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1855"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3950"},{"key":"e_1_2_8_93_1","first-page":"3395","article-title":"Identification of FGFR4\u2010activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models","volume":"119","author":"Taylor J. G.","year":"2009","journal-title":"J. Clin. Invest."},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02957.x"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.37"},{"key":"e_1_2_8_96_1","first-page":"4058","article-title":"Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription\u2010polymerase chain reaction analysis of IGH\u2010MMSET fusion transcripts","volume":"60","author":"Malgeri U.","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.634042"},{"key":"e_1_2_8_98_1","first-page":"1036","article-title":"Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis","volume":"87","author":"Soverini S.","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204465"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0797-260"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507200102"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2008.12.050"},{"key":"e_1_2_8_103_1","first-page":"1301","article-title":"Fibroblast growth factor receptor 3 S249C mutation in virus associated squamous cell carcinomas","volume":"8","author":"Shotelersuk V.","year":"2001","journal-title":"Oncol. Rep."},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-08-0021"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.11.003"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.238","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.238","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T15:06:03Z","timestamp":1696604763000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,8]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1002\/cam4.238"],"URL":"https:\/\/doi.org\/10.1002\/cam4.238","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,8]]},"assertion":[{"value":"2013-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}